Combinatorial-designed Hyaluronic Acid Nanoparticles for Tumour Targeted Drug and Small Interfering Ribonucleic Acid Delivery - Hyaluronic Acid for Biomedical and Pharmaceutical Applications - page 67

Table 3.1 Characteristics of HA derivative/siRNA particles. Illustrative examples from each class of lipid
chain that was used for derivatisation

Functionalised HA
Derivative

Self-
assembly

siRNA
encapsulation

Silencing
activity in
cancer cells

Hydrodynamic diameter of the siRNA
encapsulated nanoparticles (nm)

Charge (mV) +
siRNA

HA-butylamine in water
(C 4 )

- - - - -

HA-hexylamine in
water (C 6 )

+ - - 1000 ± 1.0 -20 ± 0.8

HA-octylamine in water
(C 8 )

+ - - 200 ± 0.3 -20 ± 0.4

HA-stearylamine in
water (C 18 )

+ - - 190 ± 0.3 -15 ± 0.6

HA-1,6 diaminohexane
in water

+ + - 320 ± 0.5 -8.0 ± 0.9

HA-1,8 diaminooctane
in water

+ + - 225 ± 0.2 -10 ± 0.1

HA-choline in water + + - 175 ± 0.4 0.0 ± 0.1
HA-SP in water + + + 190 ± 0.3 +16.5 ± 0.9
HA-PEI in water + + + 180 ± 0.1 -14.5 ± 0.4
HA-PEI in PBS + + + 50 ± 0.9 -15.0 ± 0.5
+: Indicates that there was effect. If those functionalised HA derivatives self-assembled in water as in the irst column, or
encapsulated siRNA as in the second column, or showed target knockdown as in the third column.